Impact of Exenatide on Sleep in Type 2 Diabetes

NCT01136798 · Completed

Last updated 2026-05-28

This clinical trial tested whether the medication exenatide could improve deep, restorative sleep in adults with type 2 diabetes who also have sleep-disordered breathing.

Status Completed The study has finished.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 18 people

Who can join Ages 18+ · all sexes

Timeline Started 2010-06 · est. completion 2016-09

Where 2 sites · United States

What this study is testing ClinicalTrials.gov NCT01136798 ↗

Description as written by the study sponsor.

The investigators propose a pilot study to test the novel hypothesis that Exenatide treatment in patients with type 2 diabetes results in improved sleep duration and quality and to explore the relationship between improvements in sleep and measures of metabolic and circadian function. This project would be the first to probe the relationship between incretin hormone regulation, duration and intensity of sleep, glucose tolerance and circadian dysfunction in diabetic patients.

Treatments tested

Exenatide Drug

Exenatide or placebo medication administered subcutaneously 5 mcg twice daily for 2 weeks, followed by 10 mcg twice daily for 4 weeks
Placebo Drug

Exenatide or placebo medication administered subcutaneously 5 mcg twice daily for 2 weeks, followed by 10 mcg twice daily for 4 weeks

Main thing measured	Non-REM Slow Wave Sleep
Sponsor	University of Chicago
Conditions studied	Type 2 Diabetes, Sleep Disordered Breathing
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01136798 ↗